Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split

Company Overview - Evogene Ltd. is a computational biology company focused on revolutionizing life-science-based product development through big data and artificial intelligence, aiming to enhance success rates while reducing development time and costs [3][10] - The company operates through five subsidiaries, each leveraging unique tech engines for product development [4][5] Reverse Share Split - A reverse share split at a ratio of 1-for-10 was approved by shareholders and is set to be implemented after market close on July 24, 2024 [10] - Post-split, the number of issued and outstanding Ordinary Shares will decrease from approximately 50,790,000 to about 5,079,000 [4][10] - The company's registered share capital will remain at NIS 3,000,000 but will be divided into 15,000,000 Ordinary Shares with a par value of NIS 0.2 each [4][10] Shareholder Impact - No fractional Ordinary Shares will be issued; fractional shares will be rounded to the nearest whole share, with no cash payments for fractional shares [2] - Proportionate adjustments will be made to the number of shares issuable upon the exercise of outstanding options and Restricted Share Units (RSUs) [2]